Quick Takeaways
- Bionik Laboratories Corp. has 6 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are not currently available.
Insider Transactions Reported by 6 Insiders of Bionik Laboratories Corp.
- Location
- Watertown, MA
What Changed
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 08 May 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Bionik Laboratories Corp. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Remi Gaston-Dreyfus | Director, 10%+ Owner | $2,987,403 | Mixed | 13 Jun 2023 | ||
| Andre-Jacques Auberton-Herve | Director | $729,068 | Mixed | 13 Jun 2023 | ||
| Charles Matine | Director | $124,191 | Mixed | 09 Jun 2023 | ||
| Richard Paul Russo Jr. | CEO and President | Mixed | 06 Oct 2022 | |||
| Daniel Gonsalves | Executive Vice President & CFO | Mixed | 06 Oct 2022 | |||
| Loren W. Wass | Chief Commercialization Officer | Mixed | 14 Oct 2021 |
Top shareholders of Bionik Laboratories Corp. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Remi Gaston-Dreyfus |
3/4/5
|
Director, 10%+ Owner |
—
class O/S missing
|
4,979,005
|
$2,987,403 | — | 13 Jun 2023 | |
| Andre-Jacques Auberton-Herve |
3/4/5
|
Director |
—
mixed-class rows
|
1,215,114
mixed-class rows
|
$729,068 | — | 13 Jun 2023 | |
| Charles Matine |
3/4/5
|
Director |
—
class O/S missing
|
206,985
|
$124,191 | — | 09 Jun 2023 | |
| Richard Paul Russo Jr. |
3/4/5
|
CEO and President |
—
class O/S missing
|
60,000
|
— | — | 06 Oct 2022 | |
| Loren W. Wass |
3/4/5
|
Chief Commercialization Officer |
—
class O/S missing
|
55,000
|
— | — | 14 Oct 2021 |
Recent Insider Transactions by Companies or Individuals for Bionik Laboratories Corp.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* An asterisk sign (*) next to the price indicates that the price is likely invalid.